Elicio Therapeutics Inc. - Asset Resilience Ratio

Latest as of March 2022: 22.84%

Elicio Therapeutics Inc. (ELTX) has an Asset Resilience Ratio of 22.84% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Elicio Therapeutics Inc. (ELTX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$18.56 Million

Cash + Short-term Investments

Total Assets

$81.26 Million

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Elicio Therapeutics Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Elicio Therapeutics Inc..

Liquid Assets Composition Over Time

This chart breaks down Elicio Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Elicio Therapeutics Inc. debt and liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$18.56 Million	22.84%
Total Liquid Assets	$18.56 Million	22.84%

Asset Resilience Insights

Good Liquidity Position: Elicio Therapeutics Inc. maintains a healthy 22.84% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Elicio Therapeutics Inc. Industry Peers by Asset Resilience Ratio

Compare Elicio Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Vaxcyte Inc NASDAQ:PCVX	Biotechnology	41.54%
Enliven Therapeutics Inc. NASDAQ:ELVN	Biotechnology	83.46%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.12%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for Elicio Therapeutics Inc. (None–None)

The table below shows the annual Asset Resilience Ratio data for Elicio Therapeutics Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Elicio Therapeutics Inc.

NASDAQ:ELTX USA Biotechnology

Market Cap

$49.41 Million

Market Cap Rank

#21997 Global

#4900 in USA

Share Price

$1.88

Change (1 day)

+0.53%

52-Week Range

$1.87 - $14.85

All Time High

$257.40